<DOC>
	<DOCNO>NCT01785316</DOCNO>
	<brief_summary>A randomize control , open-label , multi-centre study evaluate Isolated Hepatic Perfusion ( IHP ) increase Overall Survival compare Best Alternative Care ( BAC ) patient isolate liver metastasis uveal melanoma .</brief_summary>
	<brief_title>The Scandinavian Randomized Controlled Trial Isolated Hepatic Perfusion Uveal Melanoma Liver Metastases</brief_title>
	<detailed_description>Uveal melanoma common primary intraocular malignancy adult . Despite successful control primary tumor , metastatic disease ultimately develop approximately 50 % patient . The liver common site metastasis , 50 % patient isolate liver metastasis . These metastasis generally refractory systemic chemotherapy median survival patient liver metastases 6 month . Regardless treatment , mortality rate approximately 90 % 2 year 1 % patient survive 5 year . Isolated hepatic perfusion ( IHP ) regional treatment first perform 40 year ago ( Aust Ausman 1960 ) . During IHP , liver completely isolated systemic circulation , allow high concentration chemotherapy perfuse liver minimal systemic exposure . In previous study institution , IHP analyse base improvement procedure result show improved outcome together minimize morbidity mortality time . A phase II follow-up study confirm IHP promising technique tolerable morbidity . There yet randomize trial compare overall survival IHP , attempt answer question investigator register study show 14 month increase survival comparing patient treat IHP long survive patient Sweden time period .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<criteria>1 . Male female age 18 year . 2 . Signed date write informed consent start specific protocol procedure . 3 . Histologically cytologically proven liver metastasis uveal melanoma . If possible time randomization , biopsy mandatory start treatment . 4 . Liver metastases measurable MRI ( prefer ) CT thorax abdomen accord RECIST version 1.1 least one unidimensional measurable lesion â‰¥ 10 mm . The examination within 4 week prior randomization . 5 . ECOG performance status 0 1 . 6 . No previous chemotherapy , radiotherapy , biologic therapy uveal melanoma metastasis ( ie firstline therapy ) 7 . Adequate hepatic function ( define ASAT , ALAT , bilirubin &lt; = 3*ULN PKINR &lt; = 1.5 ) medical history liver cirrhosis portal hypertension 1 . More 50 % liver volume ( measure CT MRI ) replace tumour . 2 . Evidence extrahepatic disease PETCT 3 . Life expectancy le 4 month 4 . Pregnant breastfeeding . Women childbearing potential must negative pregnancy test perform within seven day prior start study . 5 . Active infection . 6 . Ischemic cardiac disease history congestive heart failure LVEF &lt; 40 % . 7 . COPD chronic pulmonary disease PFT 's indicate FEV &lt; 50 % predicted age . 8 . Reduced renal function define SCreatinine &gt; =1.5xULN Creatinine Clearance &lt; 40 mL/min , calculate use Cockroft Gault formula . 9 . Reduced blood leukocyte platelet define LPK &lt; 2.0x109/L TPK &lt; 100x109/L 10 . Use live vaccine four week start study . 11 . Body mass index 35 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Perfusion Cancer Chemotherapy , Regional</keyword>
</DOC>